ArticleBMC cancer2025
DDR1 drives cervical cancer progression and immune evasion: a bioinformatics analysis with experimental verification.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- DDR1 in esophageal squamous cell carcinoma: bioinformatics discovery and experimental validation.Translational cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCervical cancer remains a major threat to women's health worldwide. Discoidin domain receptor 1 (DDR1) drives immune evasion in a variety of cancers, but its expression pattern, clinical significance, and immunoregulatory mechanisms in cervical cancer have not been clarified.
methodsDDR1 expression profiles were resolved based on TCGA and GEPIA2 databases; DDR1-related pathways were enriched by GO/KEGG/GSEA; immunohistochemistry was performed in 40 cases of cervical cancer and 20 cases of normal tissues to assess the association of the DDR1 protein with clinicopathological features and survival prognosis for clinical validation. In addition, the biological role of DDR1 in cervical cancer was detected by Western blot, CCK8 and transwell.
resultsDDR1 was significantly overexpressed in cervical cancer and correlated with advanced FIGO stage and poor overall survival; DDR1 can promote the proliferation and migration of cervical cancer cells, and at the same time affect immune escape by reshaping the tumor microenvironment and metabolic reprogramming.
conclusionDDR1 is able to remodel the immunosuppressive microenvironment. Targeting DDR1 may overcome immune escape and provide a new therapeutic strategy for cervical cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.